A small clinical-stage biotech company that more than doubled in price on Wednesday had previously attracted a large group of high-profile hedge fund managers.
Shares of Axovant Sciences surged 160 percent, to close at $4.55, on Wednesday after the company announced it licensed the exclusive worldwide rights to develop and commercialize an investigational gene therapy for Parkinson’s disease from Oxford BioMedica.
The
